StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Moderna (MRNA) PT Raised to $160 at RBC Capital
June 3, 2024 6:40 AM
RBC Capital analyst Luca Issi raised the price target on Moderna (NASDAQ: MRNA) to $160.00 (from $135.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Form 4 Moderna, Inc. For: May 29 Filed by: AFEYAN NOUBAR
May 31, 2024 7:00 PM
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 2:09 PM
Moderna (MRNA) Announces FDA Approval for mRESVIA
May 31, 2024 2:00 PM
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 2:00 PM
Moderna (MRNA) Receives U.S. FDA Approval for RSV Vaccine mRESVIA
May 31, 2024 11:00 AM
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 11:00 AM
Form 4 Moderna, Inc. For: May 28 Filed by: Mock James M
May 30, 2024 4:36 PM
Form 4 Moderna, Inc. For: May 28 Filed by: Klinger Shannon Thyme
May 30, 2024 4:29 PM
Form 4 Moderna, Inc. For: May 28 Filed by: Hoge Stephen
May 30, 2024 4:15 PM
Midday movers: Salesforce, Kohl's and Agilent fall; Foot Locker, HP rise
May 30, 2024 7:48 AM
Moderna (MRNA) rises on FT report about bird flu vaccines
May 30, 2024 7:40 AM
